STTR Phase I: Neuromodulation by Electromagnetic (EM) Energy-Induced Hypersound

STTR 第一阶段：通过电磁 (EM) 能量诱导超声进行神经调节

• 批准号: 2136383
• 负责人: Chad Andresen
• 金额: $ 25.6万
• 依托单位: HYPERSOUND MEDICAL, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-15 至 2023-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136383&HistoricalAwards=false
• 关键词: STTR; Phase; Neuromodulation; Electromagnetic; EM

The broader impact of this Small Business Technology Transfer (STTR) Phase I project proposes to develop a new way to block pain in the human body. This new technology offers the potential for a novel, less invasive, lower cost, non-addicting solution to pain relief. The project develops a device to be applied near or on the skin, significantly penetrating the tissue to inhibit pain. The primary market is to provide relief from back pain, which affects more than 100 M Americans. Other potential markets include pain suppression from peripheral wounds, neuralgias, migraine, cancer, diabetes-related neuropathies, and degenerative diseases, such as the rheumatoid group. This Small Business Technology Transfer Phase I Project proposes a new approach to noninvasively modulate selected neural tissues to block pain by known principles of neurological competitive inhibition. The technology employs electromagnetic energy in a novel electrostrictive mode of action within the dielectric nature of cellular media to remotely evoke ultrasound as well as higher frequency hypersound forces in-situ. These induced forces are hypothesized to result in biological effects through the well-known action of cellular stretch activation. This project will further develop instrumentation to produce unique microwave device designs and determine the effects of microwave variables on neuromodulation. The research institution will apply the developed instrumentation on rat and neuronal cell models to define the important operating parameters for ensuring therapeutic safety and efficacy.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这一小型企业技术转移（STTR）I阶段项目的更广泛影响提议开发一种阻止人体疼痛的新方法。这项新技术为一种新颖，侵入性较低，成本较低，无成名的解决方案提供了潜力，以缓解疼痛。该项目开发了一个要在皮肤附近或皮肤上应用的设备，可显着穿透组织以抑制疼痛。主要市场是减轻背部疼痛，这会影响超过100 m的美国人。其他潜在的市场包括抑制周围伤口，神经痛，偏头痛，癌症，与糖尿病相关的神经病和退化性疾病，例如类风湿组。这个小型企业转移阶段I项目提出了一种新的方法，用于非侵入性调节选定的神经组织，以通过已知的神经竞争抑制原理阻止疼痛。该技术在细胞介质的介电性质内采用电磁能，以远程引起超声波和更高的频率高度发达力在原地中。假设这些诱导的力是通过众所周知的细胞拉伸活化作用而导致生物学作用的。该项目将进一步开发仪器以生成独特的微波设备设计，并确定微波变量对神经调节的影响。研究机构将将开发的仪器应用于大鼠和神经元细胞模型，以确定确保治疗安全性和有效性的重要操作参数。该奖项反映了NSF的法定任务，并被认为值得通过基金会的知识分子优点和更广泛的影响标准通过评估来进行评估。